Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642990 · ClinicalTrials.gov registry record · Phase 2
NR in Chemo-induced Peripheral Neuropathy
A Phase 2 study, sponsored by Donna Hammond, PhD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03642990: Clinical Trial Phase 2 study, sponsored by Donna Hammond, PhD.
NCT03642990 is a Phase 2 study that was terminated before completion, run by Donna Hammond, PhD. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03642990, a Phase 2 study, was terminated before completion, sponsored by Donna Hammond, PhD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Primary Outcome
The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe sym
Interventions
- DRUG Nicotinamide Riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 2 |
Why NCT03642990 stopped before completion
NCT03642990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Nicotinamide Riboside is the first listed.
NCT03642990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03642990 about?
NCT03642990 is a clinical study titled "NR in Chemo-induced Peripheral Neuropathy". The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistan...
What is the current status of trial NCT03642990?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-11-08. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03642990?
The interventions under investigation include: Nicotinamide Riboside (DRUG).
Who is sponsoring clinical trial NCT03642990?
This trial is sponsored by Donna Hammond, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03642990's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI